GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Month 30 & 42 Extension Studies of CRD-004 Primary Study
- Conditions
- Herpes Zoster
- Interventions
- Procedure: Blood sampling for assay of persistence of immunogenicity
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT00492648
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: Cervarix™ (HPV-16/18 L1 VLP AS04)
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00492544
- Locations
GSK Investigational Site
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
- Conditions
- Rhinitis, Allergic, Perennial
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 239
- Registration Number
- NCT00490204
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1461
- Registration Number
- NCT00490568
- Locations
- 🇬🇧
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
- Conditions
- TetanusDiphtheriaAcellular Pertussis
- Interventions
- Procedure: Taking of blood samplesBiological: BoostrixBiological: Adacel
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1954
- Registration Number
- NCT00489970
- Locations
- 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age
- Conditions
- Streptococcus Pneumoniae VaccinesInfections, Streptococcal
- Interventions
- Biological: SynflorixBiological: Infanrix hexaBiological: Rotarix
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 230
- Registration Number
- NCT00489554
- Locations
- 🇲🇽
GSK Investigational Site, Mexico, Mexico
Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden
- Conditions
- Rotavirus GastroenteritisInfections, Rotavirus
- Interventions
- Procedure: Blood sample collection
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 642
- Registration Number
- NCT00489567
Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers
- Conditions
- DyslipidaemiasHealthy Subjects
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT00488449
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
- Conditions
- Migraine Disorders
- Interventions
- Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium)
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 656
- Registration Number
- NCT00488514
- Locations
- 🇺🇸
GSK Investigational Site, Wenatchee, Washington, United States
GSK372475 Bioequivalence Study
- Conditions
- Healthy SubjectsDepressive Disorder
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 66
- Registration Number
- NCT00488098
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada